
UBS maintains Sanofi at Neutral
An UBS analyst maintained Sanofi (EPA: SASY) at Neutral and a price target of $100.00 from a prior price target of %currency%%price%. Prior to this rating, Sanofi had 16 buy ratings, 7...
An UBS analyst maintained Sanofi (EPA: SASY) at Neutral and a price target of $100.00 from a prior price target of %currency%%price%. Prior to this rating, Sanofi had 16 buy ratings, 7...
A Deutsche Bank analyst maintained Sanofi (EPA: SASY) at Hold and a price target of $85.00. Prior to this rating, Sanofi had 16 buy ratings, 7 hold ratings, and 0 sell ratings. For...
A Berenberg analyst maintained Sanofi (EPA: SASY) at Hold and a price target of $105.00 from a prior price target of %currency%%price%. Prior to this rating, Sanofi had 15 buy ratings, 8...
A Barclays analyst upgraded Sanofi (EPA: SASY) from Equalweight to Overweight with a price target of $115.00 from a prior price target of %currency%%price%. Prior to this rating, Sanofi had...
A Jefferies analyst maintained Sanofi (EPA: SASY) at Buy and a price target of $120.00. Prior to this rating, Sanofi had 15 buy ratings, 8 hold ratings, and 0 sell ratings. For consensus...
An UBS analyst maintained Sanofi (EPA: SASY) Neutral at Neutral and a price target of $93.00. Prior to this rating, Sanofi had 15 buy ratings, 8 hold ratings, and 0 sell ratings. For...
Sanofi added its "bold" decision to go without earlier-stage clinical COPD trials had shaved years off the development time
By Scott Kanowsky Investing.com -- Shares in Sanofi SA (EPA:SASY) climbed by more than 5%, as analysts noted the "blockbuster potential" of the French drugmaker's asthma and eczema medicine...
Sanofi-Regeneron stocks are trading higher today after their blockbuster drug aced the pivotal COPD trial. Sanofi SA (NASDAQ: SNY) and Regeneron Pharmaceuticals Inc's (NASDAQ: REGN) Phase 3...
New York, USA, March 23, 2023 (GLOBE NEWSWIRE) -- Chronic Myeloid Leukemia Market to Exhibit Significant Growth as Leading Companies Such as Novartis, Ascentage Pharma, Terns...
Acer Therapeutics Inc (NASDAQ: ACER) announced topline results from its Phase 2a proof of concept clinical trial to evaluate ACER-801 (osanetant) as a potential treatment for moderate to...
By Peter Nurse Investing.com - European stock markets traded sharply higher Friday, with sentiment boosted by moves in both Europe and the United States to support under-pressure lenders,...
By Peter Nurse Investing.com - European stock markets are expected to open higher Friday, with sentiment boosted by moves in both Europe and the United States to support under-pressure...
French drugmaker Sanofi said it would cut the price of some of its insulin products by as much as 78% in the U.S., joining other big diabetes drugmakers facing pressure over high...
Sanofi SNYFR:SAN said Thursday that it will cut the U.S. list price of Lantus by 78%, and it will also cap out-of-pocket costs at $35 for the same insulin for people with commercial health...
By Liz Moyer Investing.com -- Stocks are falling as the shutdown of SVB Financial Group (NASDAQ:SIVB) sends shockwaves through the banking sector. Here are the midday movers for March 10. ...
By Scott Kanowsky Investing.com -- Sanofi SA (EPA:SASY) agreed to purchase US-based pharmaceutical firm Provention Bio (NASDAQ:PRVB) in a deal worth approximately $2.9 billion, as the...
Sanofi SA (NASDAQ: SNY) has agreed to acquire Provention Bio Inc (NASDAQ: PRVB) for $25.00 per share in cash, representing an equity value of approximately $2.9 billion. The transaction adds...
Newark, New Castle, USA, March 13, 2023 (GLOBE NEWSWIRE) -- The global Influenza and COVID -19 vaccine market will be valued at 278.5 billion in 2030; the spike in cases of COVID pandemic...
By Ludwig Burger and Dina Kartit (Reuters) -France’s Sanofi has agreed to acquire Provention Bio for $2.9 billion to bolster its work on type 1 diabetes therapy and to strengthen its drug...
Sanofi to buy Provention Bio for $25 per share in deal worth $2.9 billion
French pharmaceutical group Sanofi said Monday that it will buy Provention Bio, Inc., a U.S.-based biopharmaceutical company focused on autoimmune diseases, for $25 per share in cash, in a...
Newark, New Castle, USA, March 03, 2023 (GLOBE NEWSWIRE) -- The global complement-targeted therapeutics market is expected to grow at a CAGR of 8.9% from 2022 to 2030, owing to the rising...
Eli Lilly & Co. said Wednesday it's capping out-of-pocket insulin costs at $35
The FDA approved Regeneron Pharmaceuticals Inc's (NASDAQ: REGN) and Sanofi SA's (NASDAQ: SNY) Kevzara (sarilumab) for polymyalgia rheumatica (PMR), an inflammatory rheumatic disease, The...
Newark, New Castle, USA, March 01, 2023 (GLOBE NEWSWIRE) -- According to a new market research report titled, "Global Peptide Therapeutics Market by Application (Metabolic, Cardiovascular...
ICICI Direct recommended hold rating on Sanofi India with a target price of Rs 6270 in its research report dated February 27, 2023.
Disclaimer: Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. All CFDs (stocks, indexes, futures), cryptocurrencies, and Forex prices are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. Therefore Fusion Media doesn't bear any responsibility for any trading losses you might incur as a result of using this data. Fusion Media or anyone involved with Fusion Media will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.